Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FPRX Five Prime Therapeutics	$38.00	$37.94	$2.61 ▼ $38.90	$1.77B	4.4	1.98 million shs	N/A
JAZZ Jazz Pharmaceuticals	$107.51 -0.7%	$108.14	$95.49 ▼ $148.06	$6.51B	0.33	827,456 shs	1.05 million shs
LEGN Legend Biotech	$34.00 -2.6%	$32.28	$27.34 ▼ $60.87	$6.25B	0.13	1.35 million shs	2.25 million shs
TGTX TG Therapeutics	$36.02 +2.4%	$37.18	$16.65 ▼ $46.48	$5.72B	1.94	2.95 million shs	2.61 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FPRX Five Prime Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
JAZZ Jazz Pharmaceuticals	0.00%	-0.91%	-0.52%	-24.30%	-0.43%
LEGN Legend Biotech	0.00%	-7.68%	+17.61%	-6.41%	-20.21%
TGTX TG Therapeutics	0.00%	+0.03%	+4.19%	-15.47%	+104.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	4.9086 of 5 stars	4.5	2.0	0.0	4.0	3.0	3.3	2.5
LEGN Legend Biotech	2.4147 of 5 stars	3.5	1.0	0.0	0.0	3.6	1.7	0.6
TGTX TG Therapeutics	3.4934 of 5 stars	2.4	1.0	0.0	3.5	1.4	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FPRX Five Prime Therapeutics	0.00	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	71.15% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	124.12% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	13.27% Upside

Current Analyst Ratings Breakdown

Latest FPRX, JAZZ, TGTX, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/14/2025	LEGN Legend Biotech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$88.00 ➝ $71.00
5/14/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$55.00 ➝ $55.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
4/22/2025	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$84.00 ➝ $84.00
4/16/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FPRX Five Prime Therapeutics	$14.87M	119.01	N/A	N/A	$4.13 per share	9.20
JAZZ Jazz Pharmaceuticals	$4.07B	1.60	$30.37 per share	3.54	$67.72 per share	1.59
LEGN Legend Biotech	$627.24M	9.96	N/A	N/A	$5.70 per share	5.96
TGTX TG Therapeutics	$329M	17.38	$0.12 per share	300.26	$1.43 per share	25.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FPRX Five Prime Therapeutics	-$137.20M	-$3.92	N/A	N/A	N/A	-554.71%	-75.84%	-49.08%	N/A
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	14.33	5.75	4.64	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	150.08	36.02	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest FPRX, JAZZ, TGTX, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FPRX Five Prime Therapeutics	N/A	5.35	5.35
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
LEGN Legend Biotech	0.30	5.20	5.07
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FPRX Five Prime Therapeutics	67.28%
JAZZ Jazz Pharmaceuticals	89.14%
LEGN Legend Biotech	70.89%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
FPRX Five Prime Therapeutics	6.40%
JAZZ Jazz Pharmaceuticals	4.30%
LEGN Legend Biotech	0.02%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FPRX Five Prime Therapeutics	87	46.57 million	N/A	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

FPRX, JAZZ, TGTX, and LEGN Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 20 at 3:44 AM | marketbeat.com

Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock

June 17, 2025 | benzinga.com

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

June 17, 2025 | msn.com

Yann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

June 17, 2025 | insidertrades.com

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 9, 2025 | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

June 7, 2025 | uk.finance.yahoo.com

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 6, 2025 | globenewswire.com

Wellington Management Group LLP Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading Up 6.2% - Still a Buy?

June 5, 2025 | marketbeat.com

Mackenzie Financial Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 1, 2025 | marketbeat.com

NorthCrest Asset Manangement LLC Invests $448,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 31, 2025 | marketbeat.com

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 30, 2025 | theglobeandmail.com

Man Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX)

May 29, 2025 | marketbeat.com

TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025 | seekingalpha.com

Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 28, 2025 | marketbeat.com

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 27, 2025 | globenewswire.com

Connecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FPRX, JAZZ, TGTX, and LEGN Company Descriptions

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$107.51 -0.73 (-0.67%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$107.53 +0.02 (+0.02%)

As of 06/20/2025 06:36 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Legend Biotech NASDAQ:LEGN

$34.00 -0.89 (-2.55%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$34.29 +0.29 (+0.84%)

As of 06/20/2025 07:57 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

TG Therapeutics NASDAQ:TGTX

$36.02 +0.85 (+2.42%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$36.16 +0.14 (+0.38%)

As of 06/20/2025 07:52 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time